



OPEN ACCESS

# Clinicopathological characterisation of *MTAP* alterations in gastrointestinal cancers

Gianluca Mauri <sup>1,2,3</sup>, Giorgio Patelli<sup>1,2,3</sup>, Laura Roazzi<sup>2,3</sup>, Emanuele Valtorta,<sup>4</sup> Alessio Amatu,<sup>3</sup> Giovanna Marrapese,<sup>3</sup> Erica Bonazzina,<sup>3</sup> Federica Tosi,<sup>3</sup> Katia Bencardino,<sup>3</sup> Gabriele Ciarlo,<sup>2,3</sup> Elisa Mariella,<sup>1,5</sup> Silvia Marsoni,<sup>1</sup> Alberto Bardelli,<sup>1,5</sup> Emanuela Bonoldi,<sup>4</sup> Andrea Sartore-Bianchi,<sup>2,3,6</sup> Salvatore Siena<sup>2,3</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/jcp-2023-209341>).

For numbered affiliations see end of article.

## Correspondence to

Dr Gianluca Mauri, IFOM, Milano 20139, Italy; [gianluca.mauri@unimi.it](mailto:gianluca.mauri@unimi.it)

GM, GP and LR contributed equally.

GM, GP and LR are joint first authors.

AS-B and SS are joint senior authors.

Received 9 December 2023

Accepted 3 January 2024

## ABSTRACT

**Background** Methylthioadenosine phosphorylase (*MTAP*) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, *MTAP* gene copy number loss (*MTAP* loss) confers a selective dependency on the related protein arginine methyltransferase 5. The impact of *MTAP* alterations in gastrointestinal (GI) cancers remains unknown although hypothetically druggable. Here, we aim to investigate the prevalence, clinicopathological features and prognosis of *MTAP* loss GI cancers.

**Methods** Cases with *MTAP* alterations were retrieved from The Cancer Genome Atlas (TCGA) and a real-world cohort of GI cancers profiled by next-generation sequencing. If *MTAP* alterations other than loss were found, immunohistochemistry was performed. Finally, we set a case–control study to assess *MTAP* loss prognostic impact.

**Results** Findings across the TCGA dataset (N=1363 patients) and our cohort (N=508) were consistent. Gene loss was the most common *MTAP* alteration (9.4%), mostly co-occurring with *CDKN2A/B* loss (97.7%). Biliopancreatic and gastro-oesophageal cancers had the highest prevalence of *MTAP* loss (20.5% and 12.7%, respectively), being mostly microsatellite stable (99.2%). In colorectal cancer, *MTAP* loss was rare (1.1%), while most *MTAP* alterations were mutations (5/7, 71.4%); among the latter, only *MTAP-CDKN2B* truncation led to protein loss, thus potentially actionable. *MTAP* loss did not confer worse prognosis.

**Conclusions** *MTAP* alterations are found in 5%–10% of GI cancers, most frequently biliopancreatic and gastro-oesophageal. *MTAP* loss is the most common alteration, identified almost exclusively in MSS, *CDKN2A/B* loss, upper-GI cancers. Other *MTAP* alterations were found in colorectal cancer, but unlikely to cause protein loss and drug susceptibility.

## INTRODUCTION

The mechanism of action of most targeted anti-cancer therapies is essentially the inhibition of oncogenic stimuli through tyrosine-kinase receptor blockade.<sup>1–3</sup> However, oncogene-addicted cancers eventually develop resistance under drug-induced selective pressure, limiting targeted therapy efficacy.<sup>4</sup> Thus, alternative or complementary therapeutic approaches are warranted.

Antimetabolic targeted therapies are emerging as new strategies to induce apoptosis and cell death in

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Despite being potentially druggable, the impact of methylthioadenosine phosphorylase (*MTAP*) alterations in gastrointestinal (GI) cancers is still largely unknown.

## WHAT THIS STUDY ADDS

⇒ Gene loss is the most common *MTAP* alteration, almost exclusively occurring in upper-GI, microsatellite stable, *CDKN2A/B* loss cancers. *MTAP* loss in GI cancers did not impact patients' prognostic. In colorectal cancer, *MTAP* alterations other than gene loss were found, but they were not associated to protein loss, thus unlikely druggable in ongoing trials.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Our study provides the largest clinicopathological and prognostic characterisation of *MTAP* altered GI cancers. This analysis will be instrumental in refining patients selection for clinical trials harnessing *MTAP* alterations.

cancer, given that the pharmacological restraining of certain nutrients or metabolic substrates has shown antitumour activity in preclinical models.<sup>5</sup> In this context, polyamine biosynthesis is garnering interest for its role in different cancer types.<sup>6</sup>

The *MTAP* (methylthioadenosine phosphorylase) gene encodes for an enzyme that plays a key role in polyamine metabolism and the salvage pathway of purines and methionine.<sup>7</sup> This gene is located in the human chromosome 9p21.3, close to cyclin-dependent kinase 2A and 2B (*CDKN2A* and *CDKN2B*), which are two well-known oncosuppressors involved in the regulation of the cell cycle.<sup>8</sup> *MTAP* is often codeleted with *CDKN2A/B* in a variety of cancers through chromosome 9p21.3 microdeletion events. While *MTAP* loss was initially alleged as a 'passenger' genomic event within the broader context of contiguous tumour suppressor gene loss, recent findings suggest it may also play an independent role in carcinogenesis.<sup>9–10</sup> Indeed, preclinical studies showed that *MTAP* loss promotes tumorigenesis independently from the presence of *CDKN2A/B* loss.<sup>8–11–13</sup> Homozygous loss of *MTAP* occurs in around 15% of all human cancers and seems to be associated with a more aggressive



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Mauri G, Patelli G, Roazzi L, et al. *J Clin Pathol* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jcp-2023-209341

phenotype with worse prognosis in different malignancies, such as non-small cell lung cancer.<sup>14–16</sup> Notably, *MTAP* loss is highly prevalent in thoracic cancers, reaching approximately 70% in mesothelioma and 60% in lung adenocarcinoma.<sup>17 18</sup> Regarding gastrointestinal (GI) cancers, *MTAP* loss prevalence was reported in heterogeneous case series often focusing on individual tumour types. It was reported in 30% of pancreatic cancer (PC),<sup>19 20</sup> 12%–35% of biliary tract cancer (BTC)<sup>21</sup> and approximately 20% in gastro-oesophageal cancer (GEC),<sup>22 23</sup> while data are lacking for colorectal cancer (CRC).

The loss of *MTAP* has been identified as a potential therapeutic target in cancer due to its multiple cellular effects.<sup>7 10 24</sup> In *MTAP* deficient cells, the accumulation of its substrate methylthioadenosine (MTA)<sup>24</sup> can hamper the activity of protein arginine methyltransferase 5 (PRMT5) via direct feedback.<sup>10</sup> MTA, as a structural analogue of the methyl donor S-adenosyl-L-methionine (SAM) required for PRMT5 activity, competes with SAM for binding and can effectively inhibit PRMT5 at high concentrations. PRMT5 plays a pivotal role in the methylation of various cellular substrates, including pro-proliferative kinases, histones and critical transcriptional components. Its activity stimulates cellular proliferation and biosynthesis, as showed in different tumour models. From a pharmacological standpoint, exploiting *MTAP* loss can be approached in at least two distinct ways for two primary reasons: (1) inhibition of de novo purine synthesis and (2) further inhibition of PRMT5, which can be achieved both indirectly, via the accumulation of MTA, and directly through targeted inhibitors. The loss or inhibition of PRMT5 results in altered RNA splicing and an increase in DNA damage, as highlighted in preclinical studies.<sup>24</sup> Moreover, effective targeting of polyamine biosynthesis has demonstrated potent antiproliferative and prodifferentiating effects in preclinical models<sup>7 10 25 26</sup> (figure 1).

GI cancers are among the most lethal tumours worldwide, due to a high risk of relapse and metastatisation.<sup>27</sup> Among others,

cancers arising from the biliopancreatic system retain a particularly poor prognosis owing to the early acquisition of resistance to available anticancer therapies. Identifying new exploitable mechanisms to develop effective targeted treatments is one of the most urgent needs in oncology.


In this study, we purport to assess the prevalence, clinicopathological features and prognostic impact of *MTAP* alterations in GI cancers, by leveraging publicly available repositories and integrating data from a patient cohort at our institution.

## METHODS

### The Cancer Genome Atlas PanCancer Atlas Analysis

We conducted a retrospective cohort study using data from The Cancer Genome Atlas (TCGA) accessed via the cBioPortal (<https://www.cbioportal.org/>, accessed on 25 July 2023).<sup>28 29</sup> The scope of our research was confined to GI tumours, specifically GEC, CRC, BTC and PC.<sup>30</sup> We queried for patients with unique tumour samples that had been profiled for somatic mutations and copy number alterations (CNA) of *MTAP*, among other genes.

Relevant clinical and molecular characteristics were evaluated using the information provided by the cBioPortal.<sup>28 29</sup> Further, we narrowed down our investigation to samples exhibiting homozygous *MTAP* loss, achieved by filtering the downloaded tabular list of cases according to 'MTAP homodeletion' status in the 'R' software package (V.2023.06.0+421, The R Foundation). A control group for comparative analysis was formed by subjects with diploid wild-type *MTAP* (*MTAP* unaltered cohort), excluding those patients with mutations or other *MTAP* alterations of unknown significance. We then compared clinical and molecular characteristics, progression-free survival (PFS) and overall survival (OS), between these two groups (*MTAP* loss vs diploid *MTAP* wild type) using the cBioPortal<sup>28 29</sup> and 'R' software.



**Figure 1** Therapeutic vulnerability of *MTAP* null cells by MAT2A and PRMT5 inhibitors *MTAP* loss results in intracellular accumulation of MTA, which competes with the activating cofactor SAM, causing a decrease in PRMT5 activity. PRMT5 is a key enzyme for the methylation of proliferative kinases, thus the reduction in PRMT5 activity leads to activation of oncogenic pathways. Targeting MAT2A or PRMT5 in *MTAP* null tumours is a potential therapeutic strategy. Created with BioRender.com. Me, methyl group; MTA, methylthioadenosine; MTR-1P, 5-methylthioribose-1-phosphate; MTAP, methylthioadenosine phosphorylase; PRMT5, protein arginine methyltransferase 5; SAH, S-adenosyl homocysteine; SAM, methyl donor S-adenosyl-L-methionine; WDR77, WD repeat domain 77; wt, wild type.

## Niguarda cohort analysis

From July 2019 to January 2022, we retrospectively collected the results of next-generation sequencing (NGS) analysis obtained through the FoundationOne CDx assay on archival tissue samples of advanced GI tumours at Grande Ospedale Metropolitano Niguarda, Milan, Italy. We included GI tumours only (from oesophagus to anus, liver, pancreas and biliary tract). Samples that failed the NGS analysis due to insufficient or low-quality material were excluded. Data from medical records were annotated on the REDCap platform,<sup>31</sup> together with the *MTAP* status and other molecular results for each subject with *MTAP* altered tumours, and preserved anonymously with respect to the patients' privacy. All patients accepted and signed an informed consent for molecular screening through FoundationOne CDx within GO40782/STARTRK-2 trial (NCT02568267).

We further assessed *MTAP* protein expression by immunohistochemistry (IHC) using a Rabbit polyclonal anti-*MTAP* antibody (1:200 dilution, ProteinTech, Tucson, Arizona, USA) in selected tumours harbouring *MTAP* alterations, other than *MTAP* loss, to evaluate whether these were associated with loss of protein expression, thus potentially conferring sensitivity to targeted agents currently under clinical investigation in dedicated clinical trials. As previously reported,<sup>32</sup> we consider as *MTAP* deficient only those tumours with complete absence of expression in IHC (score 0). Using the same criteria as a control we also evaluated the expression loss of the protein p16 (the product of *CDKN2A*) (p16, Clone:JC2, mouse monoclonal antibody, 1:100 dilution, Gennova, Seville, Spain), that it is commonly associated with *MTAP* loss. Immunohistochemistry analyses were performed on formalin-fixed paraffin-embedded tumour sections by an automated staining system Dako Omnis. Normal stromal cells were used as internal positive control.

Lastly, focusing on *MTAP* loss, we set a case-control study comparing GI cancers with *MTAP* loss to *MTAP* unaltered cases in a 1:2 ratio, matched by primary tumour site. While our primary interest was *MTAP* gene loss, cases with other types of *MTAP* alterations were also considered if they exhibited a complete absence of *MTAP* protein expression, as indicated by an IHC score of 0.

## Statistical analysis

Due to the potential for an inflated risk of false-positive findings from multiple hypothesis testing in the TCGA cohorts, we set a stringent prespecified level of significance at  $p < 0.001$  for all statistical analyses. Results were then validated whenever possible in our independent case-control study according to a standard prespecified  $p < 0.05$ . We used the  $\chi^2$  test for categorical data and the Wilcoxon rank-sum test for numerical data to refute the null hypothesis of no difference in variables between the *MTAP* loss and the *MTAP* unaltered cohorts (except otherwise specified). Numeric variables were expressed as medians/IQR. Median age was calculated at the time of cancer diagnosis. For survival data (ie, time to progression or censoring for PFS and time to death or censoring for OS), we employed the log-rank test to refute the null hypothesis of no difference in survival rates between the two independent cohorts. PFS and OS data from the TCGA cohorts previously proved reliable and were recommended for use.<sup>33</sup> All statistical analyses were executed in 'R' (V.2023.06.0+421, The R Foundation), except for those readily computable directly in the cBioPortal.<sup>28 29</sup>

## RESULTS

### TCGA PanCancer Atlas Analysis

An initial cohort of 1436 GI cancers was identified through cBioPortal based on the study inclusion criteria. Of these, 73 patients were excluded since the *MTAP* status had not been profiled, resulting in a selected cohort of 1363 patients. Since *MTAP* is a tumour suppressor gene reported to promote tumour growth by copy number loss,<sup>10</sup> we then focused on 128 cases exhibiting *MTAP* loss (*MTAP* loss cohort). For comparison, we also established a control cohort comprising 1224 patients who showed no *MTAP* alteration (*MTAP* unaltered cohort) (online supplemental figure 1A).

We first explored the prevalence of *MTAP* gene alterations in the overall cohort of GI cancers (N=1363), together with clinical and molecular characteristics (online supplemental table 1). This miscellaneous cohort of patients with GI cancer, primarily non-metastatic, exhibited *MTAP* alterations in 10.3% of cases (N=139), most commonly as copy number loss (9.4%, N=128), followed by mutations (0.6%, N=7) and amplification (0.3%, N=4). Clinical and molecular characteristics of *MTAP* loss, *MTAP* mutant and *MTAP* amplified GI tumours are presented in table 1.

Given that gene deletion was the most common alteration observed for *MTAP* and that its role in cancer is supported by evidence of pathogenicity,<sup>10</sup> we further focused the analysis on *MTAP* loss cases (N=128). Prevalence of *MTAP* loss events was higher in PC (22.3%), followed by GEC (12.7%) and BTC (11.1%). Conversely, *MTAP* loss was quite rare in CRC (1.1%). While addressing a genetic deletion, we investigated CNA for adjacent genes at the same chromosomal location (9p21.3). We observed nearly a complete overlap of *CDKN2A/B* loss in the *MTAP* loss cohort (97.7%, N=125), with a statistically significant odds ratio (OR) for co-occurrence ( $p < 0.001$ , two-sided Fisher's exact test).

Comparative analysis between the *MTAP* loss (N=128) and *MTAP* unaltered (N=1224), cohorts revealed significant differences among several variables (table 2). Enrichment for *MTAP* loss was confirmed in a subset of tumour types, that is, PC and GEC ( $p < 0.001$ ), while CRC was confirmed as far less represented in the *MTAP* loss population as compared with the unaltered one ( $p < 0.001$ ). Interestingly, histology distribution was also different among cases and controls ( $p < 0.001$ ): while adenocarcinoma was similarly represented as the prevalent histology, squamous cell carcinoma cases were fourfold more common in the *MTAP* loss cohort. As a key issue towards result interpretation, we highlight that almost all the reported squamous-cell cancers were oesophageal cancers in this cohort. From a molecular perspective, *MTAP* loss cases were almost exclusively classified as MSS as compared with controls (99.2% vs 86.6%,  $p < 0.001$ ), with a small difference in median TMB without clinical relevance (2.5 vs 3.3 mutations/megabase,  $p < 0.001$ ). *CDKN2A/B* loss was confirmed significantly enriched in the *MTAP* loss population (97.7% vs 8.1%,  $p < 0.001$ ), and the same result applied to the deletion of several other genes located in proximity to chromosome 9p21.3. Indeed, *MIR31HG*, *IFNA1*, *IFNA5*, *IFNA8*, *IFNE*, *LINC01239*, *DMRTA1* and *KLHL9* on the chromosome cytoband 9p21.3 were found deleted in  $\geq 50\%$  of *MTAP* loss cases (compared with  $< 2\%$  in controls,  $p < 0.001$ ). We also observed minor enrichment (deletion in  $< 50\%$  of cases) for other 75 genes spanning from 9p21.1 to 9p24.3 ( $p < 0.001$ ) (online supplemental figure 2). Regarding classical oncogenes and tumour suppressors in GI cancers, we found no difference in *TP53* and *KRAS* mutations, while *APC* mutations were less



**Table 1** Clinical and molecular characteristics of GI malignancies exhibiting *MTAP* alterations, presented as gene loss, mutations and amplification in the TCGA PanCancer Atlas Studies and the Niguarda Cancer Center cohort

	TCGA cohort (N=135)			Niguarda cohort (N=27)	
	<i>MTAP</i> loss	<i>MTAP</i> mutant	<i>MTAP</i> amplified	<i>MTAP</i> loss	<i>MTAP</i> mutant
No of patients	128	7	4	22	5
Median age (IQR)	63 (56–72)	71 (62–72)	62 (53.72)	62 (48–72)	55 (47–68)
Gender (%)					
Male	89 (69.5)	1 (14.3)	3 (75.0)	13 (59.1)	3 (60.0)
Female	39 (30.5)	6 (85.7)	1 (25.0)	9 (40.9)	2 (40.0)
Cancer type (%)					
Pancreas	40 (31.3)	0 (0.0)	1 (25.0)	12 (54.5)	0 (0.0)
Gastro-oesophageal	78 (60.9)	3 (42.9)	1 (25.0)	4 (18.2)	0 (0.0)
Colorectal	6 (4.7)	4 (57.1)	2 (50.0)	2 (9.1)*	5 (100.0)
Biliary tract	4 (3.1)	0 (0.0)	0 (0.0)	2 (9.1)	0 (0.0)
Others	0 (0.0)	0 (0.0)	0 (0.0)	2 (9.1)	0 (0.0)
Tumour histology (%)					
Adenocarcinoma	95 (74.2)	5 (71.4)	4 (100.0)	19 (86.4)	5 (100.0)†
Mucinous adenocarcinoma	2 (1.6)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)
Signet ring carcinoma	4 (3.1)	1 (14.3)	0 (0.0)	1 (4.5)	0 (0.0)
Squamous carcinoma	27 (21.1)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
Undifferentiated carcinoma	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)	0 (0.0)
Stage at diagnosis (%)					
Non metastatic	82 (64.1)	5 (71.4)	2 (50.0)	9 (40.9)	4 (80.0)
Metastatic	12 (9.4)	1 (14.3)	1 (25.0)	13 (59.1)	1 (20.0)
NA	34 (36.2)	1 (14.3)	1 (25.0)	0 (0.0)	0 (0.0)
Tumour mutational burden-high‡ (%)	4§ (3.1)	4§ (57.1)	0§ (0.0)	1 (4.5)¶	1 (20.0)
Microsatellite instability (%)	1** (0.8)	4** (57.1)	0** (0.0)	0 (0.0)	1 (20.0)
Concomitant <i>CDKN2A-CDKN2B</i> deletion (%)	125†† (97.7)	1 (14.3)	1 (25.0)	22 (100.0)	0 (0.0)
Concomitant <i>MTAP</i> loss- <i>RAS</i> mutations (%)					
Pancreatic	34 (85.0)	NA	1 (100.0)	12 (100.0)	NA
Colorectal	2 (40.0)	3 (75.0)	1 (50.0)	1 (14.3)	1 (20.0)

\*Both colorectal cancers were *RAS* and *BRAF* wild type, MSS, with low TMB.

†One adenocarcinoma had squamous foci.

‡≥10 mutations/megabase.

§Non-synonymous TMB.

¶POLE mutation found.

\*\*According to the MANTIS score with a threshold of 0.4.

††*CDKN2A* in 97.7% of cases, while *CDKN2B* in 92.2%. *CDKN2A* loss always reported for all *CDKN2B* loss cases, co-occurrence 118/128 cases. Log2 OR >3, p<0.001 (derived from two-sided Fisher's exact test).

GI, gastrointestinal; MANTIS, Microsatellite Analysis for Normal-Tumor Instability; MSS, Microsatellite stable; *MTAP*, methylthioadenosine phosphorylase; NA, not applicable; OR, Odds ratio; TCGA, The Cancer Genome Atlas; TMB, Tumour mutational burden.

common (7.1% vs 35.5%,  $p<0.001$ ) and *ERBB2* amplifications more common (16.4% vs 7.5%,  $p=0.001$ ) in case of *MTAP* loss, again likely due to the low prevalence of CRC and high prevalence of GEC in this population. Focusing on individual tumour types, the analysis was not powered to identify differences in subpopulations. As such, we could only observe a trend towards a higher incidence of *KRAS* mutations in *MTAP* loss PC as compared with the unaltered counterpart—85.0% (34/40) vs 60.1% (83/138),  $p=0.003$ . At the transcriptomic level, there was a significant association between *MTAP* copy number loss and decreased gene expression (online supplemental figure 3).

We performed survival analysis (online supplemental figure 4). Patients with *MTAP* loss showed unfavourable PFS (17.06 months, 95%CI 13.15 to 24.33 vs 42.31 months, 95%CI 36.03 to 63.42,  $p<0.001$ ) and a trend towards worse OS (20.35 months, 95%CI 17.92 to NA vs 49.38 months, 95%CI 44.74 to 58.55,  $p=0.002$ ). However, after performing a multivariate Cox proportional hazards model to investigate the impact of *MTAP* loss and different GI cancer types on patient

prognosis, this result did not reach statistical significance (HR=0.79,  $p=0.097$ ). Indeed, when we included the type of cancer in our model, we found significant differences in PFS between different cancer types, with significantly worse PFS for PC (HR=3.13,  $p<0.001$ ), BTC (HR=3.11,  $p<0.001$ ) and GEC (HR=1.89,  $p<0.001$ ). Since we previously observed a different distribution of cancer types according to *MTAP* status with a higher frequency of more aggressive cancer types in the *MTAP* loss group, this uneven distribution may explain the observed difference in PFS between the two cohorts, rather than the *MTAP* classification itself. Indeed, there was no survival difference according to *MTAP* status when addressing different tumour types separately (figure 2A,B and online supplemental figure 5).

### Niguarda cohort analysis

We analysed NGS reports of 558 GI tumours. Sequencing failed for 50 samples, leaving an initial cohort of 508 GI cancer patients


**Table 2** Clinical and molecular characteristics of GI malignancies exhibiting *MTAP* loss as compared with *MTAP* unaltered GI tumours from the TCGA PanCancer Atlas Studies

	<i>MTAP</i> loss	<i>MTAP</i> unaltered	P value
No of patients	128	1224	
Median age (IQR)	63 (56–72)	66 (57–74)	0.151
Sex (%)			0.039
Male	89 (69.5)	730 (59.6)	
Female	39 (30.5)	462 (40.2)	
NA	0 (0.0)	2 (0.2)	
Cancer type (%)			<0.001
Gastro-oesophageal	78 (60.9)	534 (43.6)	
Pancreatic	40 (31.3)	138 (11.3)	
Colorectal	6 (4.7)	520 (42.5)	
Biliary	4 (3.1)	32 (2.6)	
Tumour histology (%)			<0.001
Adenocarcinoma	95 (74.2)	1002 (81.9)	
Mucinous adenocarcinoma	2 (1.6)	75 (6.1)	
Signet ring carcinoma	4 (3.1)	80 (6.5)	
Squamous carcinoma	27 (21.1)	67 (5.5)	
Stage at diagnosis (%)			0.495
Non metastatic	82 (64.1)	931 (76.1)	
Metastatic	12 (9.4)	103 (8.4)	
NA	34 (36.2)	190 (15.5)	
Tumour mutational burden* (median (IQR))	2.5 (1.6–4.1)	3.3 (2.07–5.3)	<0.001
Microsatellite instability† (%)	1 (0.8)	164 (13.4)	<0.001
<i>CDKN2A/B</i> loss (%)	125 (97.7)	57 (8.1)	<0.001
<i>TP53</i> mutant (%)	84 (65.6)	703 (57.4)	0.044
<i>KRAS</i> mutant (%)	41 (32.0)	332 (27.1)	0.253
<i>BRAF</i> V600E mutant (%)	1 (0.8)	48 (3.9)	0.080
<i>APC</i> mutant (%)	6 (7.1)	435 (35.5)	<0.001
<i>ERBB2</i> amplification	21 (16.4)	92 (7.5)	0.001

\*Nonsynonymous TMB.  
†According to the MANTIS score with a threshold of 0.4.  
GI, gastrointestinal; MANTIS, Microsatellite Analysis for Normal-Tumor InStability; NA, not available; TCGA, The Cancer Genome Atlas; TMB, Tumour mutational burden.

to be screened for *MTAP* alterations (329 CRC, 80 PC, 47 GEC, 36 BTC, 16 small bowel or other tumours). *MTAP* alterations were found in 27 (5.3%) (online supplemental figure 1B). Characteristics of patients are reported in table 1. Overall, most patients (14/27, 51.8%) were metastatic at diagnosis. Adenocarcinoma was the most common histology (25/27, 92.6%). *MTAP* alterations were found in PC (12/80, 15.0%), GEC (4/47, 8.5%) and BTC (2/36, 5.5%), CRC (7/329, 2.1%), and others including small bowels (2/16, 12.5%) (online supplemental table 2). Homozygous *MTAP* loss was the main deleterious alteration retrieved (22/27, 81.5%), followed by mutations (5/27, 18.5%), although differences were noticed according to primary tumour histology.

All tumour types but CRC were characterised by gene loss as the only *MTAP* genetic alteration. In fact, all *MTAP* alterations other than gene loss were retrieved in CRC, that was indeed enriched with 5/7 alterations being mutations (three reported as pathogenic: splice site 34–1G>A, A191fs\*6, *MTAP*-*CDKN2B* truncation; two as variants of unknown significance). One of these cases was hypermutated due to microsatellite instability. In all 5 *MTAP* mutant samples from CRC patients, we performed IHC analysis to investigate the genomic effect on protein expression. Only



**Figure 2** No difference in survival analysis of pancreatic cancer patients according to *MTAP* status in the TCGA PanCancer Atlas cohort (A, B) and the Niguarda Cancer Center cohort (C, D). *MTAP*, methylthioadenosine phosphorylase; TCGA, The Cancer Genome Atlas.


*MTAP*-*CDKN2B* truncation as assessed by NGS led to complete lack of *MTAP* expression (IHC 0), coupled with absence of p16 proteins expression (IHC 0) despite no CNA for *CDKN2A/B* was reported; this annotation suggests that both *MTAP* and *CDKN2B* were involved in a truncation event leading to absence of translation to the protein level, differently from other somatic variants with no or minor impact on the protein level. In all other cases, *MTAP* protein expression was retained (figure 3). We performed IHC in a case of CRC harbouring *MTAP* loss: although there was minimal heterogeneity in staining, 90%–98% of cancer cells did not express *MTAP* protein, as compared with intense and homogeneous protein expression in proficient cases.

Focusing on *MTAP* loss, all cases were microsatellite stable (100%) and *CDKN2A/B* deleted (100%). Given that PC was most represented in our cohort, we built a case–control study with a 1:2 ratio in PC patients (table 3). We found no significant difference in terms of clinical and molecular features apart from a higher prevalence of *CDKN2A/B* loss (100% vs 4.2%,  $p<0.001$ ). Survival analysis did not show any difference for both PFS to first-line treatment and OS according to *MTAP* status (figure 2C,D).

DISCUSSION

In our study, we found that *MTAP* alteration prevalence in GI cancers ranges from 5% to 10% across various cancer types. We reported here that PC, GEC and BTC show the highest prevalence of *MTAP* loss among GI cancers (15%–22%, 9%–13%, 6%–11%, respectively). Conversely, CRC showed a lower incidence of *MTAP* alterations (2%), which were mostly mutations rather than gene loss. These results are in line with previous reports on the prevalence of *MTAP* alterations in GI cancers, confirming the enrichment of such molecular feature in upper-GI malignancies.<sup>19–23</sup> In addition, our findings bring new knowledge regarding the very low prevalence of *MTAP* loss in lower-GI tumours (<1% in CRC).

Similar to other non-GI malignancies, *MTAP* and *CDKN2A/B* loss co-occurred in almost all cases. Moreover, in more than 50% of cases *MTAP* loss co-occurred with the loss of other genes



**Figure 3** Immunohistochemistry (IHC) staining of two cases of metastatic colorectal cancer harbouring *MTAP* alterations other than gene loss. (A, B) Samples were collected from a patient in which an *MTAP-CDKN2B* truncation was identified by next-generation sequencing (NGS), in which both *MTAP* and *p16* IHC revealed a complete lack of expression for both proteins, respectively. (C, D) Samples were collected from a patient in which *MTAP* M140V point mutation was identified by NGS, in which both *MTAP* and *p16* protein expression was maintained, respectively. *MTAP* IHC staining was performed using a rabbit polyclonal anti-*MTAP* antibody (1:200 dilution, Pro-teinTech, Tucson, AZ). As a control, we also evaluated the expression of the protein *p16* (the product of *CDKN2A* gene) using the *p16*, Clone:JC2, mouse monoclonal antibody (1:100 dilution, Gennova, Sevilla). Only samples with complete *MTAP* and/or *p16* protein loss were considered *MTAP* deficient (IHC score 0).

located on chromosomal locus 9p21.3, thus leading to postulate that *MTAP* loss could be related to a large-scale chromosome deletion. We also investigated the potential clinical impact of *MTAP* mutations, that is, currently unknown. In our cohort, only one mutation out of five led to IHC protein loss, thereby limiting the potential use of targeted approaches in this setting.

Regarding prognosis, we found no association between *MTAP* loss and PFS and OS. Indeed, the higher prevalence of biliopancreatic cancers among *MTAP* loss cancers emerged as the actual

driver of worse prognosis rather than the *MTAP* loss itself. Accordingly, in patients identified in the Niguarda series we did not observe any survival difference among *MTAP* loss and proficient cases. These data are in line with another recent study on BTC in which *MTAP* loss was not prognostic.<sup>34</sup>

Even if the overall results from both the cohorts are comparable, there are also some differences. First, the TCGA cohort is larger but less clinically detailed than our institutional cohort. Besides, in the TCGA nearly 75% of patients were affected by non-metastatic tumours, whereas all patients had metastatic cancers in our cohort. Finally, CRC was the most common histology in our cohort due to centre-specific enrichment, while GEC squamous tumours, in which *MTAP* loss plays an important role in carcinogenesis, accounted for only a minority of cases.<sup>14</sup>

Beyond *MTAP* loss, we found five out of seven *MTAP* altered CRC cases harbouring alterations other than gene loss. Given the availability of clinical trials targeting cancers with *MTAP* loss (online supplemental table 3), we performed IHC to test whether protein expression in these five cases was retained, but we found that only the *MTAP-CDKN2B* truncation led to protein loss, thus potentially having a clinical impact predisposing to sensitivity to *MTAP* targeted treatment strategies.

Our study has also limitations. First, no functional assessment of *MTAP* mutations has been performed. Second, the retrospective nature of the study and the limited sample size of some GI subset in the present cohort represent a further limitation. Third, the analysis was underpowered to distinguish small-effect size differences within individual tumour types, especially given the small numerosity of *MTAP* loss CRC and BTC. Finally, we acknowledge that all GEC in the Niguarda cohort were adenocarcinomas as a possible limitation, differently from the TCGA cohort. Indeed, since we retrieved molecular profiles data from GO40782/STARTRK-2 clinical trial screening (NCT02568267), according to physicians choice at our institution mostly adenocarcinoma patients rather than squamous cell cancer patients were screened for trial enrolment.

In conclusion, this is the first study investigating *MTAP* alterations prevalence in different GI cancers, also focusing on concomitant genetic alterations and addressing *MTAP* loss also at the transcriptomics and proteomics levels. We found that *MTAP* loss occurs almost exclusively in MSS tumours and it co-occurs with *CDK2NA/B* and/or other 9p21.3-located gene loss in almost all cases. *MTAP* loss was more common in upper-GI cancers (PC, BTC and GEC), compared with lower GI-cancers (ie, CRC). However, *MTAP* loss did not impact GI cancer prognosis. In CRC, we also identified *MTAP* alterations other than gene loss but, since protein loss was uncommon in these cases, it is unlikely that they may impact clinical outcomes and therapeutic targetability in GI cancers.

#### Author affiliations

<sup>1</sup>IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy  
<sup>2</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy  
<sup>3</sup>Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy  
<sup>4</sup>Department of Pathology, Grande Ospedale Metropolitano Niguarda, Milan, Italy  
<sup>5</sup>Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy  
<sup>6</sup>Division of Research and Innovation, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy

**Handling editor** Yoh Zen.

**Acknowledgements** GM and GP are PhD students within the European School of Molecular Medicine (SEMM). EM was supported by the FIRC-AIRC 'Michele e Carlo Ardigzone' fellowship for Italy.

**Table 3** Clinical and molecular characteristics of *MTAP* loss versus *MTAP* unaltered pancreatic cancer patients from the Niguarda Cancer Center cohort

	<i>MTAP</i> loss cohort	<i>MTAP</i> intact cohort	P value
No of patients	12	24	
Median age at diagnosis (IQR)	63 (51–72)	65 (57–71)	0.750
Gender (%)			
Male	5 (41.7)	14 (58.3)	0.483
Female	7 (58.3)	10 (41.7)	
Stage at diagnosis (%)			0.725
Non metastatic	5 (41.7)	13 (54.2)	
Metastatic	7 (58.3)	11 (45.8)	
Tumour mutational burden (IQR)	1.26 (0.00–4.10)	2.52 (1.58–4.73)	0.210
Microsatellite instability (%)	0.0	0.0	NA
<i>CDKN2A/B</i> loss (%)	12 (100.0)	1 (4.2)	<0.001
<i>RAS</i> mutant (%)	23 (95.8)	12 (100.0)	1.000
<i>MTAP</i> , methylthioadenosine phosphorylase; NA, not available.			



**Contributors** GMauri conceived and wrote the manuscript, collected and analysed data. GP and LR wrote the manuscript, collected and analysed data. EV and EBonaldi retrieved samples and performed the immunohistochemistry analysis. AA, GC and GMarrapese collected the data. EBonazzina, FT and KB analysed the data and critically reviewed the manuscript. SM, AB, AS-B and SS reviewed, edited and supervised manuscript preparation and development. AS-B and SS are joint last authors. SS is the guarantor of the content of this article.

**Funding** This study was supported by Fondazione Oncologia Niguarda Onlus. The research leading to these results received funding from AIRC IG 2017—project ID 20685—P.I. Salvatore Siena (SS); AIRC under IG 2018—ID. 21923 project—P.I. Bardelli Alberto (AB); AIRC under 5 per Mille 2018—ID. 21091 programme—P.I. Bardelli Alberto (AB), G.L. Silvia Marsoni (SM), G.L. Salvatore Siena (SS); European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (TARGET, grant agreement no 101020342) (AB); International Accelerator Award, ACRCelebrate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB) and AIRC (22795) (AB); IMI contract no 101007937 PERSIST-SEQ (AB).

**Competing interests** AB reports personal fees from Guardant Health and Invivata during the conduct of the study as well as grants from AstraZeneca, Boehringer-Ingelheim and Neophore outside the submitted work; in addition, AB is a shareholder of Neophore and Kither. SS is an advisory board member for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi-Sankyo, Guardant Health, Merck, Novartis, Roche-Genentech and Seagen. AS-B reports personal fees from Amgen, Bayer, Servier, Guardant Health and Novartis during the conduct of the study. GMauri and GP received honoraria from COR2ED.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** This study involves human participants and all patients accepted and signed an informed consent for molecular screening through FoundationOne CDx within GO40782/STARTRK-2 trial (NCT02568267). Clinical data were obtained by informed consent for publication of anonymised data according to standard internal consent form at Niguarda Cancer Center ('Consent Form for the Acquisition of Personal Data for Clinical Research (ex. Art. 9 GDPR), Epidemiological Research and Epidemiological Study Purposes', Mod02888 Rev. 4, 18 February 2020). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Gianluca Mauri <http://orcid.org/0000-0002-7646-0973>

## REFERENCES

- Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016;17:738–46.
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472–80.
- Remon J, Steuer CE, Ramalingam SS, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. *Ann Oncol* 2018;29:120–7.
- Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. *Nature* 2019;575:299–309.
- Stine ZE, Schug ZT, Salvino JM, et al. Targeting cancer metabolism in the era of precision oncology. *Nat Rev Drug Discov* 2022;21:141–62.
- Casero RA, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. *Nat Rev Cancer* 2018;18:681–95.
- Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 Axis. *Cell Rep* 2016;15:574–87.
- Bertino JR, Waud WR, Parker WB, et al. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity. *Cancer Biology & Therapy* 2011;11:627–32.
- Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. *Cancer Res* 1996;56:1083–90.
- Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. *Science* 2016;351:1214–8.
- Fedorin A, Rajapurkar SR, O'Brien S, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. *Cancer Cell* 2019;36:100–114.
- Kadariya Y, Yin B, Tang B, et al. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. *Cancer Res* 2009;69:5961–9.
- Kadariya Y, Tang B, Wang L, et al. Germline mutations in Mtap cooperate with Myc to accelerate tumorigenesis in mice. *PLoS ONE* 2013;8:e67635.
- Lin X, Yan C, Gao Y, et al. Genetic variants at 9p21.3 are associated with risk of esophageal squamous cell carcinoma in a Chinese population. *Cancer Sci* 2017;108:250–5.
- Su C-Y, Chang Y-C, Chan Y-C, et al. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. *Eur J Surg Oncol* 2014;40:1143–50.
- Marcé S, Balagué O, Colomo L, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. *Clin Cancer Res* 2006;12:3754–61.
- Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. *Clin Cancer Res* 2003;9:2108–13.
- Ashok Kumar P, Graziano SL, Danziger N, et al. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. *Cancer Med* 2023;12:1157–66.
- Yu S, Doyle LA, Hornick JL, et al. The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens. *Cancer Cytopathol* 2023. 10.1002/cncy.22777 [Epub ahead of print 6 Dec 2023].
- Hustinx SR, Huban RH, Leoni LM, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periaampullary cancer: a potential new target for therapy. *Cancer Biol Ther* 2005;4:83–6.
- Karikari CA, Mullendore M, Eshleman JR, et al. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. *Mol Cancer Ther* 2005;4:1860–6.
- Powell EL, Leoni LM, Canto MI, et al. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. *Am J Surg Pathol* 2005;29:1497–504.
- Cheng X-Y, Liu Z, Shang L, et al. Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells. *Oncotargets Ther* 2017;10:5855–62.
- Kalev P, Hyer ML, Gross S, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. *Cancer Cell* 2021;39:209–24.
- Mavrakis KJ, McDonald ER 3rd, Schlachach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. *Science* 2016;351:1208–13.
- Mariella E, et al. Transcriptome-wide gene expression Outlier analysis pinpoints therapeutic Vulnerabilities in colorectal cancer. *Accepted for Publication in Molecular Oncology* 2024.
- Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. *CA Cancer J Clin* 2023;73:17–48.
- Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4.
- Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013;6:pl1.
- The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The cancer genome atlas Pan-Cancer analysis project. *Nat Genet* 2013;45:1113–20.
- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform* 2019;95:103208.
- Alhalabi O, Zhu Y, Hamza A, et al. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. *Eur Urol Oncol* 2023;6:228–32.
- Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA Pan-Cancer clinical data resource to drive high-quality survival outcome analytics. *Cell* 2018;173:400–16.
- Gaspar CF, Ngoy NY, Tang T, et al. Abstract 963: clinical impact of MTAP status in advanced cholangiocarcinoma: genomic profile and response to treatment. *Cancer Res* 2023;83:963.